Drug-induced myopathy is muscle damage or weakness caused by a medication you’re taking. It ranges from mild muscle aches to severe weakness that makes everyday tasks like climbing stairs or standing up from a chair difficult. In rare cases, it can progress to a dangerous breakdown of muscle tissue called rhabdomyolysis, which can damage the kidneys. The condition is most commonly linked to cholesterol-lowering statins, but dozens of other drug classes can cause it too.
How It Feels
The onset is usually gradual. The first thing most people notice is that their muscles feel weaker, not just sore. You might struggle to climb a flight of stairs, have trouble getting out of a low chair, or find it harder to lift your arms above your head. This weakness tends to affect the large muscles closest to the trunk of your body, particularly the thighs and hips first, then the shoulders. It typically appears on both sides of the body equally.
Muscle pain is common but not universal. Some people have significant weakness with little or no pain, while others experience aching and cramping as the primary symptom. Exercise intolerance, where physical activity feels disproportionately exhausting, is another hallmark. Symptoms can appear within weeks of starting a new medication or develop after years of use.
At its most severe, drug-induced myopathy causes rhabdomyolysis, where muscle fibers break apart rapidly. This releases proteins into the bloodstream that can overwhelm the kidneys. Signs of rhabdomyolysis include extreme muscle pain, dark or cola-colored urine, and pronounced weakness. This is a medical emergency.
Which Medications Cause It
Statins are the most recognized culprits. Roughly 40% of statin users report some degree of muscle symptoms, though severe myopathy is rare, occurring in about 0.08% of users. The risk varies by specific statin: FDA adverse event data shows that lovastatin, simvastatin, and atorvastatin carry a several-times-greater risk of rhabdomyolysis compared to pravastatin, rosuvastatin, or fluvastatin. Higher doses increase risk substantially, with data from large trials suggesting a 10-fold increase in myopathy for patients on high-dose statin therapy versus lower doses.
Beyond statins, the medications most commonly associated with myopathy include:
- Corticosteroids: Long-term use (for conditions like asthma, autoimmune diseases, or transplant management) can cause a distinct form of steroid myopathy with proximal weakness.
- Colchicine: Used for gout, it can produce symptoms resembling an autoimmune muscle disease, with weakness and pain in the large muscles of the arms and legs.
- Antimalarials: Chloroquine and hydroxychloroquine (also used for lupus and rheumatoid arthritis) can damage the cellular recycling machinery inside muscle fibers.
- Antiretrovirals: Zidovudine, an older HIV medication, caused myopathy in 17% of patients treated for longer than 9 months. Newer antivirals like telbivudine and raltegravir also carry risk.
- Amiodarone: A heart rhythm medication that can damage muscle fibers over time.
- Immune checkpoint inhibitors: Cancer immunotherapy drugs can trigger a form of muscle inflammation where pain is the earliest symptom in about 80% of cases, often before weakness appears.
- Cyclosporine: An immune-suppressing drug that can cause muscle pain, weakness, and elevated muscle enzymes.
Chronic heavy alcohol use also causes a toxic myopathy through similar mechanisms.
How Medications Damage Muscle
Different drugs injure muscle tissue in different ways, which is why the symptoms and severity vary so much depending on the medication involved.
Some drugs, particularly certain antiretrovirals and statins, impair the energy-producing structures inside muscle cells (mitochondria). When these structures stop working efficiently, muscles can’t generate enough energy to function, leading to weakness and fatigue. Other medications, like chloroquine and amiodarone, interfere with the cell’s waste-disposal system. Cellular debris accumulates inside muscle fibers, gradually disrupting their structure. Still others directly damage the structural proteins that allow muscles to contract, or they alter calcium levels inside muscle cells in ways that trigger fiber breakdown.
Corticosteroids work differently from most other drug-induced myopathies. Rather than killing muscle fibers outright, long-term steroid use causes specific types of muscle fibers to shrink and weaken, a process called atrophy. This is why steroid myopathy often shows normal levels of muscle enzymes in blood tests, unlike most other forms where those levels are elevated.
How It’s Diagnosed
No single test confirms drug-induced myopathy. Diagnosis relies on connecting your symptoms and medication history with a combination of tests.
A blood test measuring creatine kinase (CK), an enzyme released by damaged muscle, is usually the first step. Levels above 1.5 times the upper limit of normal (adjusted for gender and ethnicity) are considered significant and warrant further investigation. Markedly elevated CK is common in necrotizing and inflammatory forms of drug-induced myopathy, but in steroid myopathy, CK levels are often completely normal.
Electromyography (EMG), which measures the electrical activity of muscles, can help distinguish myopathy from nerve-related causes of weakness. It may show characteristic patterns of muscle irritability, or it may appear normal in milder cases. MRI can reveal areas of muscle inflammation or damage. In uncertain cases, a muscle biopsy provides the most definitive information, showing the specific pattern of damage, whether that’s fiber death, inflammation, or accumulation of abnormal material inside cells.
One of the trickiest diagnostic situations involves patients already being treated for autoimmune muscle diseases with steroids. When these patients develop new weakness, it can be genuinely difficult to tell whether the underlying disease is flaring up or the steroid itself is causing the problem. Often the only way to sort this out is to carefully reduce the steroid dose and watch what happens.
Treatment and Recovery
The cornerstone of treatment is stopping or changing the offending medication. Early recognition and discontinuation can prevent progression to rhabdomyolysis and permanent damage. In many cases, your doctor will work with you to find an alternative medication that achieves the same therapeutic goal with less muscle risk. For statin users, for example, switching to a lower-risk statin at a lower dose is a common strategy.
Recovery timelines depend on the type of damage and how long the medication was used. Corticosteroid-induced myopathy is almost always reversible. Improvement typically begins within 3 to 4 weeks of tapering the dose, though full recovery can take months to a year. For other drug-induced myopathies, resolution after stopping the medication is the general rule, but the timeline varies. Mild cases with only pain and no structural damage tend to resolve within weeks. Cases involving significant fiber destruction take longer.
A rare but important exception is statin-associated immune-mediated necrotizing myopathy (IMNM). In this condition, the statin appears to trigger an autoimmune reaction against muscle tissue that continues even after the drug is stopped. This form is very rare, occurring at an estimated rate of about 1 to 5 per million statin users annually, but it requires immune-suppressing treatment beyond simple drug discontinuation.
Risk Factors That Increase Vulnerability
Not everyone taking these medications develops myopathy. Several factors raise the risk. Higher doses are consistently linked to greater risk across nearly all drug classes. Impaired kidney or liver function can slow the body’s clearance of medications, effectively increasing exposure to muscle tissue. Older age, smaller body size, and the use of multiple interacting medications all compound the risk.
For statins specifically, a genetic variant in a gene called SLCO1B1 affects how the body processes certain statins, leading to higher drug levels in the blood and greater muscle exposure. Pharmacogenomic testing for this variant is increasingly available and can help guide statin selection. Taking statins alongside certain other medications, such as cyclosporine, some antibiotics, or antifungal drugs, can dramatically increase statin blood levels and myopathy risk.
People with pre-existing neuromuscular conditions or untreated thyroid disorders are also more susceptible. Even strenuous exercise around the time of starting a new medication can temporarily raise CK levels and potentially increase vulnerability to muscle injury.